A generic method for design of oligomer-specific antibodies

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Brännström, Kristoffer ^a   Lindhagen Persson, Malin ^a   Gharibyan, Anna L ^a   Iakovleva, Irina ^a   Vestling, Monika ^a   Sellin, Mikael E ^a   Brännström, Thomas ^a   Morozova Roche, Ludmilla ^a   Forsgren, Lars ^a   Olofsson, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OLIGOMER; POLYPEPTIDE; ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; PROTEIN; PROTEIN BINDING;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENERIC METHOD; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MOUSE; NONHUMAN; PARKINSON DISEASE; PROCESS DESIGN; PROCESS OPTIMIZATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; STOICHIOMETRY; TURNOVER TIME; VALIDATION PROCESS; ANIMAL; ANTIBODY AFFINITY; CHEMISTRY; HIPPOCAMPUS; IMMUNOLOGY; KINETICS; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; EPITOPES; FEMALE; HIPPOCAMPUS; KINETICS; MICE; PARKINSON DISEASE; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEINS;

EID: 84897516039     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090857     Document Type: Article

References (59)

1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, et al. (2012) Amyloid fibril protein nomenclature: 2012 recommendations from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 19: 167-170.
2. Larson ME, Lesne SE (2012) Soluble Abeta oligomer production and toxicity. J Neurochem 120 Suppl 1: 125-139.
3. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurotoxic tau oligomers. Biochemistry 49: 10039-10041.
4. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95: 6448-6453.
5. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539. (Pubitemid 34288854)
6. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A 97: 571-576. (Pubitemid 30070350)
7. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, et al. (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4: 887-893. (Pubitemid 32801591)
8. Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159: 1993-2000. (Pubitemid 33104254)
9. Benilova I, Karran E, De Strooper B (2012) The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15: 349-357.
10. Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, et al. (2012) Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One 7: e32014.
11. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489. (Pubitemid 36444329)
12. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, et al. (2006) Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 83: 374-384. (Pubitemid 43184401)
13. Lambert MP, Velasco PT, Viola KL, Klein WL (2009) Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets 8: 65-81.
14. Morgado I, Wieligmann K, Bereza M, Ronicke R, Meinhardt K, et al. (2012) Molecular basis of beta-amyloid oligomer recognition with a conformational antibody fragment. Proc Natl Acad Sci U S A.
15. Tomic JL, Pensalfini A, Head E, Glabe CG (2009) Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358.
16. Morgado I, Wieligmann K, Bereza M, Ronicke R, Meinhardt K, et al. (2012) Molecular basis of beta-amyloid oligomer recognition with a conformational antibody fragment. Proc Natl Acad Sci U S A 109: 12503-12508.
17. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, et al. (2010) Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Abeta oligomers. Mol Neurodegener 5: 57.
18. O'Nuallain B, Wetzel R (2002) Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A 99: 1485-1490. (Pubitemid 34136519)
19. Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66: S74-78. (Pubitemid 43739989)
20. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, et al. (2006) Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem 281: 4292-4299. (Pubitemid 43847859)
21. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, et al. (2007) Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100: 23-35. (Pubitemid 46085837)
22. Leliveld SR, Korth C (2007) The use of conformation-specific ligands and assays to dissect the molecular mechanisms of neurodegenerative diseases. J Neurosci Res 85: 2285-2297. (Pubitemid 47204744)
23. Shughrue PJ, Acton PJ, Breese RS, Zhao WQ, Chen-Dodson E, et al. (2010) Anti-ADDL antibodies differentially block oligomer binding to hippocampal neurons. Neurobiol Aging 31: 189-202.
24. Haupt C, Morgado I, Kumar ST, Parthier C, Bereza M, et al. (2011) Amyloid fibril recognition with the conformational B10 antibody fragment depends on electrostatic interactions. J Mol Biol 405: 341-348.
25. Tayebi M, Jones DR, Taylor WA, Stileman BF, Chapman C, et al. (2011) PrP(Sc)-specific antibodies with the ability to immunodetect prion oligomers. PLoS One 6: e19998.
26. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM (2012) Structure-based design of conformation- and sequence-specific antibodies against amyloid beta. Proc Natl Acad Sci U S A 109: 84-89.
27. Arai H, Glabe C, Luecke H (2012) Crystal structure of a conformation-dependent rabbit IgG Fab specific for amyloid prefibrillar oligomers. Biochim Biophys Acta 1820: 1908-1914.
28. Shankar GM, Walsh DM (2009) Alzheimer's disease: synaptic dysfunction and Abeta. Mol Neurodegener 4: 48.
29. Lindhagen-Persson M, Brannstrom K, Vestling M, Steinitz M, Olofsson A (2010) Amyloid-beta oligomer specificity mediated by the IgM isotype-implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS One 5: e13928.
30. Fawzi NL, Ying J, Ghirlando R, Torchia DA, Clore GM (2011) Atomic-resolution dynamics on the surface of amyloid-beta protofibrils probed by solution NMR. Nature 480: 268-272.
31. Olofsson A, Sauer-Eriksson AE, Ohman A (2006) The solvent protection of alzheimer amyloid-beta-(1-42) fibrils as determined by solution NMR spectroscopy. J Biol Chem 281: 477-483. (Pubitemid 43671210)
32. Robert R, Lefranc MP, Ghochikyan A, Agadjanyan MG, Cribbs DH, et al. (2010) Restricted V gene usage and VH/VL pairing of mouse humoral response against the N-terminal immunodominant epitope of the amyloid beta peptide. Mol Immunol 48: 59-72.
33. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, et al. (2007) Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2: 18.
34. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B, et al. (2007) Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol 113: 389-402. (Pubitemid 46421628)
35. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17: 427-442.
36. Bidinosti M, Shimshek DR, Mollenhauer B, Marcellin D, Schweizer T, et al. (2012) Novel one-step immunoassays to quantify alpha-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem 287: 33691-33705.
37. Park MJ, Cheon SM, Bae HR, Kim SH, Kim JW (2011) Elevated levels of alpha-synuclein oligomer in the cerebrospinal fluid of drug-naive patients with Parkinson's disease. J Clin Neurol 7: 215-222.
38. Walsh DM, Klyubin I, Shankar GM, Townsend M, Fadeeva JV, et al. (2005) The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biochem Soc Trans 33: 1087-1090. (Pubitemid 41659119)
39. Treusch S, Hamamichi S, Goodman JL, Matlack KE, Chung CY, et al. (2011) Functional links between Abeta toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science 334: 1241-1245.
40. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457. (Pubitemid 34454251)
41. Lobello K, Ryan JM, Liu E, Rippon G, Black R (2012) Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. Int J Alzheimers Dis 2012: 628070.
42. Delrieu J, Ousset PJ, Caillaud C, Vellas B (2012) 'Clinical trials in Alzheimer's disease': immunotherapy approaches. J Neurochem 120 Suppl 1: 186-193.
43. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, et al. (2009) A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73: 2061-2070.
44. Bae EJ, Lee HJ, Rockenstein E, Ho DH, Park EB, et al. (2012) Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission. J Neurosci 32: 13454-13469.
45. Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6: e19338.
46. Valera E, Masliah E (2013) Immunotherapy for neurodegenerative diseases: Focus on alpha-synucleinopathies. Pharmacol Ther.
47. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 118: 658-667.
48. Castillo-Carranza DL, Lasagna-Reeves CA, Kayed R (2013) Tau aggregates as immunotherapeutic targets. Front Biosci (Schol Ed) 5: 426-438.
49. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R (2011) Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res 8: 659-665.
50. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B (2009) Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology. J Neurochem 111: 192-203.
51. Mougenot AL, Nicot S, Bencsik A, Morignat E, Verchere J, et al. (2011) Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging.
52. Kawasaki Y, Freire E (2011) Finding a better path to drug selectivity. Drug Discov Today 16: 985-990.
53. Vilches-Moure JG, Ramos-Vara JA (2005) Comparison of rabbit monoclonal and mouse monoclonal antibodies in immunohistochemistry in canine tissues. J Vet Diagn Invest 17: 346-350. (Pubitemid 41003480)
54. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, et al. (2012) Passive immunization against pyroglutamate-3 amyloid-beta reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener Dis 10: 265-270.
55. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, et al. (2012) An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 32: 9677-9689.
56. Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, et al. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19: 1377-1379. (Pubitemid 41113755)
57. Doty PM, G(1953) Low molecular weight proteins. 2. Thermodynamics of the association of insulin molecules. Discuss Faraday Soc 13: 51-58.
58. Lindhagen-Persson M, Vestling M, Reixach N, Olofsson A (2008) Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. Amyloid 15: 240-245.
59. O'Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267: 5421-5426.